UA86962C2 - Viral polymerase inhibitors - Google Patents

Viral polymerase inhibitors

Info

Publication number
UA86962C2
UA86962C2 UAA200609971A UAA200609971A UA86962C2 UA 86962 C2 UA86962 C2 UA 86962C2 UA A200609971 A UAA200609971 A UA A200609971A UA A200609971 A UAA200609971 A UA A200609971A UA 86962 C2 UA86962 C2 UA 86962C2
Authority
UA
Ukraine
Prior art keywords
polymerase inhibitors
viral polymerase
compound
polymerases
viral
Prior art date
Application number
UAA200609971A
Other languages
English (en)
Russian (ru)
Inventor
Юла С. Тсантризос
Катерин Шабо
Пьер Луи Болье
Кристиан Брошю
Мартен Пуарье
Тимоти А. Стаммерс
Боункхам Тавонекхам
Жан Ранкур
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA86962(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of UA86962C2 publication Critical patent/UA86962C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UAA200609971A 2004-02-20 2005-02-18 Viral polymerase inhibitors UA86962C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54621304P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
UA86962C2 true UA86962C2 (en) 2009-06-10

Family

ID=34886250

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200609971A UA86962C2 (en) 2004-02-20 2005-02-18 Viral polymerase inhibitors
UAA200811052A UA94602C2 (en) 2004-02-20 2005-02-18 Viral polymerase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200811052A UA94602C2 (en) 2004-02-20 2005-02-18 Viral polymerase inhibitors

Country Status (30)

Country Link
US (3) US7582770B2 (enExample)
EP (2) EP2626354A1 (enExample)
JP (4) JP4648333B2 (enExample)
KR (2) KR101320907B1 (enExample)
CN (6) CN103333162A (enExample)
AR (2) AR047706A1 (enExample)
AU (1) AU2005215829C1 (enExample)
BR (1) BRPI0507861A (enExample)
CA (1) CA2553879C (enExample)
DK (1) DK1718608T3 (enExample)
EA (3) EA201301284A1 (enExample)
EC (1) ECSP066780A (enExample)
ES (1) ES2431314T3 (enExample)
HR (1) HRP20130971T1 (enExample)
IL (2) IL177537A (enExample)
IN (1) IN2012DN04853A (enExample)
MY (1) MY144718A (enExample)
NO (1) NO20064004L (enExample)
NZ (1) NZ549079A (enExample)
PE (1) PE20051141A1 (enExample)
PL (1) PL1718608T3 (enExample)
PT (1) PT1718608E (enExample)
RS (1) RS52931B (enExample)
SG (2) SG150511A1 (enExample)
SI (1) SI1718608T1 (enExample)
TW (2) TWI368508B (enExample)
UA (2) UA86962C2 (enExample)
UY (1) UY28758A1 (enExample)
WO (1) WO2005080388A1 (enExample)
ZA (1) ZA200605151B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
RS52931B (sr) * 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CA2597680A1 (en) 2005-02-11 2006-08-17 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
CA2618682C (en) 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
EP2120952A4 (en) * 2007-01-15 2011-09-21 Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe ANTIVIRAL COMPOUNDS AND METHODS OF USE
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2463284A1 (en) 2007-02-27 2012-06-13 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
CN101754970B (zh) 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
AU2008297015B2 (en) 2007-08-30 2013-08-22 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2320905B1 (en) 2008-08-11 2017-06-28 Glaxosmithkline LLC Novel adenine derivatives
MX2011001662A (es) 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
MX2011002602A (es) * 2008-09-17 2011-04-07 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina.
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
PL2368890T3 (pl) * 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
WO2010149359A1 (en) * 2009-06-26 2010-12-29 Lonza Ltd Process and intermediates for the preparation of benzimidazolecarboxylic acids
JP2012533569A (ja) * 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
WO2011094489A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
EA021048B1 (ru) 2010-02-10 2015-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
TW201208704A (en) 2010-07-14 2012-03-01 Vertex Pharma Palatable pharmaceutical composition
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
CN103228278A (zh) * 2010-09-30 2013-07-31 贝林格尔.英格海姆国际有限公司 治疗hcv感染的组合疗法
MA34548B1 (fr) 2010-09-30 2013-09-02 Boehringer Ingelheim Int Formes solides d'un inhibiteur puissant du vhc
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
CN103408430B (zh) * 2013-08-30 2014-09-17 南京理工大学 一种2-甲基-4-硝基苯甲酸的合成方法
ES2655940T3 (es) 2014-02-20 2018-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano
CN104130143B (zh) * 2014-08-06 2017-02-15 江苏鼎龙科技有限公司 3‑甲氨基‑4‑硝基苯氧乙醇的制备方法
BR112017009648A2 (pt) 2014-11-13 2017-12-19 Glaxosmithkline Biologicals Sa composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
RU2018137389A (ru) 2016-04-07 2020-05-12 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
ES2921855T3 (es) 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
CN105884627A (zh) * 2016-04-22 2016-08-24 成都东电艾尔科技有限公司 一种氧烯洛尔药物中间体邻氨基苯酚的合成方法
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US10660334B2 (en) 2016-08-15 2020-05-26 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
WO2019162174A1 (de) 2018-02-21 2019-08-29 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US20230357125A1 (en) * 2022-05-06 2023-11-09 AMPAC Fine Chemicals Process for Catalytic Reduction of Nitro Compounds to Amines
CN115304584B (zh) * 2022-07-25 2023-05-26 云南大学 3-硫甲基-(5’-芳基-1h-吡唑)-吲哚类化合物及其制备方法和用途

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094903A (en) 1964-03-26 1967-12-13 Smith Kline French Lab Improvements in or relating to nitrofuran derivatives
FR1604809A (en) 1965-11-26 1972-04-17 Thiazolyl benzimidazoles - animal feed additives
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
NL6917115A (enExample) 1968-11-22 1970-05-26
US3565912A (en) 1969-01-27 1971-02-23 Upjohn Co 5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
DE2346316C2 (de) 1973-09-14 1985-02-14 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von 2-Furylbenzimidazolen
GB1521471A (en) 1974-06-05 1978-08-16 Randall & Son Ltd J Token-deposit locks
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
US4003908A (en) 1976-03-11 1977-01-18 E. R. Squibb & Sons, Inc. Derivatives of imidazo(4,5-b)pyridines
CH632628B (de) 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4264325A (en) 1977-02-22 1981-04-28 Ciba-Geigy Corporation Phenyl-benzimidazolyl-furanes for optical brightening of organic materials
DE2720111A1 (de) 1977-05-05 1978-11-16 Agfa Gevaert Ag Korrosionsschutzmittel fuer zweibad-stabilisatorbaeder
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
DE2852531A1 (de) 1978-12-05 1980-06-19 Bayer Ag Benzofuranyl-benzimidazole
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
US4384121A (en) 1979-11-01 1983-05-17 Ciba-Geigy Corporation Cationic fluorescent whitening agents
GR75101B (enExample) 1980-10-23 1984-07-13 Pfizer
GB8707798D0 (en) 1987-04-01 1987-05-07 Ici Plc Recovery of metals
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB2118552A (en) 1982-04-15 1983-11-02 Pfizer Ltd Thromboxane synthetase inhibitors
JPS60149502A (ja) 1984-01-12 1985-08-07 Kuraray Co Ltd インド−ル系農園芸用殺菌剤
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8707051D0 (en) 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
GB8609175D0 (en) 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
US4859684A (en) 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US4957932A (en) 1987-11-25 1990-09-18 Merck Frosst Canada, Inc. Benzoheterazoles
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
JPH03157646A (ja) 1989-11-15 1991-07-05 Konica Corp ハロゲン化銀写真感光材料
JPH03219232A (ja) 1990-01-24 1991-09-26 Konica Corp 分光増感されたハロゲン化銀写真感光材料
JPH05507469A (ja) 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
JP2909645B2 (ja) 1990-05-28 1999-06-23 コニカ株式会社 ハロゲン化銀カラー写真感光材料
US5110494A (en) 1990-08-24 1992-05-05 Man-Gill Chemical Company Alkaline cleaner and process for reducing stain on aluminum surfaces
KR100222252B1 (ko) 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121463D0 (en) 1991-10-10 1991-11-27 Smithkline Beecham Corp Medicament
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JPH05165163A (ja) 1991-12-11 1993-06-29 Konica Corp 色素画像形成方法
JP3013124B2 (ja) 1991-12-26 2000-02-28 コニカ株式会社 カラー画像形成方法
US5216003A (en) 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5314796A (en) 1992-04-02 1994-05-24 Konica Corporation Silver halide color photographic light sensitive material
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
CZ141795A3 (en) 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
JP3213426B2 (ja) 1993-02-19 2001-10-02 エーザイ株式会社 ６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
EP0615159B1 (en) 1993-03-04 2004-09-22 Fuji Photo Film Co., Ltd. Silver halide photographic material
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
JP3156444B2 (ja) 1993-06-02 2001-04-16 松下電器産業株式会社 短波長レーザ光源およびその製造方法
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
EP0669323B2 (de) 1994-02-24 2004-04-07 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
CA2124169A1 (en) 1994-05-24 1995-11-25 Richard Mcculloch Keenan Chemical compounds
US5912260A (en) 1994-05-27 1999-06-15 James Black Foundation Limited Gastrin and CCK antagonists
ES2159648T3 (es) 1994-11-29 2001-10-16 Dainippon Pharmaceutical Co Derivado de indol.
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
DE19507913C2 (de) 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
EP0820441B1 (en) 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
US6444694B1 (en) 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
JP3544245B2 (ja) 1995-06-09 2004-07-21 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法
EP0791582A4 (en) 1995-08-04 1997-12-10 Otsuka Kagaku Kk DERIVATIVES OF INDOLE-2-CARBOXYLIC ACID ESTERS, AND BACTERICIDES FOR AGRICULTURE AND HORTICULTURE CONTAINING THEM AS ACTIVE INGREDIENTS
KR100388345B1 (ko) 1995-10-05 2004-03-30 교토 야쿠힝 고교 가부시키가이샤 신규헤테로시클릭유도체및이것의의약용도
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JPH09124632A (ja) 1995-10-31 1997-05-13 Sankyo Co Ltd ベンゾヘテロ環誘導体
CA2241186C (en) 1995-12-28 2006-02-14 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
AUPO118896A0 (en) 1996-07-23 1996-08-15 Fujisawa Pharmaceutical Co., Ltd. New use
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
CA2276042C (en) 1996-12-26 2002-10-08 Michika Takano N-hydroxyurea derivatives and medicinal compositions containing the same
JPH10204059A (ja) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
PT968206E (pt) 1997-02-19 2007-02-28 Pharmacopeia Inc Derivados n-heterocíclicos como inibidores de nos
WO1998037069A1 (en) 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11177218A (ja) 1997-12-12 1999-07-02 Tamura Kaken Co Ltd 電子回路用金属面具備部品及びその表面保護剤
US6271390B1 (en) 1998-05-22 2001-08-07 Avanir Pharmaceuticals Suppression of the IgE-dependent allergic response by benzimidazole analogs
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
RU2227458C2 (ru) 1998-06-18 2004-04-27 Новартис Аг Применение бензазольных соединений в качестве репеллента, композиция их содержащая и способ получения композиции
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6445525B1 (en) * 1998-07-16 2002-09-03 Seagate Technology Llc Disc drive performance by reducing areal data storage density
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
US6228868B1 (en) 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
KR20010099623A (ko) 1998-08-21 2001-11-09 비로파마 인코포레이티드 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PT1129091E (pt) 1998-11-12 2003-02-28 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos relacionados
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
WO2000039099A1 (en) 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2368630A1 (en) 1999-04-02 2000-10-12 Ruth R. Wexler Aryl sulfonyls as factor xa inhibitors
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6478874B1 (en) 1999-08-06 2002-11-12 Engelhard Corporation System for catalytic coating of a substrate
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP2001122855A (ja) 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
ES2196926T3 (es) 1999-10-28 2003-12-16 Eoc Surfactants Nv Procedimiento para la preparacion de disolucion concentrada fluida de betaina.
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
RU2223761C2 (ru) * 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
WO2001051487A1 (en) 1999-12-28 2001-07-19 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
AU2001235278A1 (en) 2000-02-18 2001-08-27 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
EP1278743A4 (en) 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100372218B1 (ko) 2000-06-29 2003-02-14 바이오인포메틱스 주식회사 유기산을 생산하는 균주 및 이를 이용한 유기산의 생산방법
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
WO2002020497A1 (en) 2000-09-01 2002-03-14 Shionogi & Co., Ltd. Compounds having anti-hepatitis c virus effect
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CN100391967C (zh) 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
EP1346724A4 (en) 2000-12-26 2004-11-17 Mitsubishi Pharma Corp AGENT FOR TREATING HEPATITIS C
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1370682A2 (en) 2001-03-08 2003-12-17 Boehringer Ingelheim (Canada) Ltd. Assay for identifying inhibitors of the rna dependent rna polymerase (ns5b) of hcv
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
AU2002329970A1 (en) 2001-09-04 2003-03-18 Isis Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2003037262A2 (en) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Novel anit-infectives
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
US20050009873A1 (en) 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
JP2005515172A (ja) 2001-11-02 2005-05-26 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
WO2003042265A1 (fr) 2001-11-13 2003-05-22 Toray Industries, Inc. Polymere et lentilles ophthalmologiques realisees a l'aide de ce polymere
EP1450809A4 (en) 2001-11-14 2006-07-19 Biocryst Pharm Inc NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
EP1572705A2 (en) 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
JP2005526102A (ja) 2002-04-01 2005-09-02 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスｒｎａ依存性ｒｎａポリメラーゼのピラノンおよびピランジオン阻害剤
KR100516434B1 (ko) 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
AU2003237088A1 (en) 2002-04-23 2003-11-10 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
GB0211418D0 (en) 2002-05-17 2002-06-26 Glaxo Group Ltd Compounds
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
ATE481106T1 (de) 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
EP1511751B1 (en) 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
CA2488842A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside analogs as rna-antivirals
NZ537359A (en) 2002-06-25 2006-10-27 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions for transdermal delivery
EP1572945A2 (en) 2002-06-27 2005-09-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
AP2005003211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
MXPA05000256A (es) 2002-07-01 2005-07-15 Upjohn Co Inhibidores de polimerasa ns5b del vhc.
EP1532128A1 (en) 2002-07-01 2005-05-25 Pharmacia & Upjohn Company LLC Inhibitors of hcv ns5b polymerase
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
PL1615613T3 (pl) 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
SG160224A1 (en) 2003-05-12 2010-04-29 Affymax Inc Novel peptides that bind to the erythropoietin receptor
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
EP1493440A1 (en) * 2003-07-03 2005-01-05 Rinoru Oil Mills Co., Ltd. Prophylactic agent of hypertension containing a conjugated fatty acid as an effective ingredient and the use thereof
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
RS52931B (sr) * 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
BRPI0508505A (pt) 2004-03-08 2007-07-31 Boehringer Ingelheim Pharma processo para acoplamento cruzado de indóis
CA2558051C (en) 2004-03-16 2013-03-12 Boehringer Ingelheim International Gmbh Palladium catalyzed indolization of 2-bromo or chloroanilines
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
CA2597680A1 (en) 2005-02-11 2006-08-17 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles

Also Published As

Publication number Publication date
PL1718608T3 (pl) 2013-11-29
TW201138770A (en) 2011-11-16
EP1718608A1 (en) 2006-11-08
TWI368508B (en) 2012-07-21
SI1718608T1 (sl) 2013-11-29
DK1718608T3 (da) 2013-10-14
PT1718608E (pt) 2013-08-01
TWI368507B (en) 2012-07-21
US7879851B2 (en) 2011-02-01
SG150511A1 (en) 2009-03-30
JP2010195818A (ja) 2010-09-09
US20050222236A1 (en) 2005-10-06
AR047706A1 (es) 2006-02-08
MY144718A (en) 2011-10-31
IL177537A (en) 2013-04-30
RS52931B (sr) 2014-02-28
NO20064004L (no) 2006-09-06
CN103319464A (zh) 2013-09-25
JP5394978B2 (ja) 2014-01-22
EP1718608B1 (en) 2013-07-17
IL219150A0 (en) 2012-06-28
JP4648333B2 (ja) 2011-03-09
US7582770B2 (en) 2009-09-01
EP1718608A4 (en) 2009-10-28
EA013207B1 (ru) 2010-04-30
EA201301284A1 (ru) 2014-03-31
AR093144A2 (es) 2015-05-20
CN101648944A (zh) 2010-02-17
ZA200605151B (en) 2008-04-30
PE20051141A1 (es) 2006-01-30
CA2553879C (en) 2011-02-22
JP2010280740A (ja) 2010-12-16
ES2431314T3 (es) 2013-11-26
UA94602C2 (en) 2011-05-25
US8030309B2 (en) 2011-10-04
KR20070005635A (ko) 2007-01-10
EA200901463A1 (ru) 2010-08-30
ECSP066780A (es) 2006-12-20
JP2007523094A (ja) 2007-08-16
KR20120091276A (ko) 2012-08-17
WO2005080388A1 (en) 2005-09-01
TW200539878A (en) 2005-12-16
JP2013237708A (ja) 2013-11-28
CN103304541A (zh) 2013-09-18
CN1922174A (zh) 2007-02-28
IN2012DN04853A (enExample) 2015-09-25
UY28758A1 (es) 2005-09-30
CA2553879A1 (en) 2005-09-01
BRPI0507861A (pt) 2007-07-17
US20090170859A1 (en) 2009-07-02
HRP20130971T1 (hr) 2013-11-08
SG184700A1 (en) 2012-10-30
KR101320907B1 (ko) 2013-10-22
NZ549079A (en) 2010-08-27
IL177537A0 (en) 2006-12-10
EP2626354A1 (en) 2013-08-14
AU2005215829B2 (en) 2012-02-09
EA200601457A1 (ru) 2007-06-29
AU2005215829C1 (en) 2012-08-30
CN103333162A (zh) 2013-10-02
CN102911161A (zh) 2013-02-06
AU2005215829A1 (en) 2005-09-01
US20110015203A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
UA86962C2 (en) Viral polymerase inhibitors
MX2007000007A (es) Inhibidores de polimerasa viral.
MXPA05007754A (es) Inhibidores de polimerasa viral.
ATE411078T1 (de) Acylsulfonamid-verbindungen als inhibitoren der rna-abhängigen rna-polymerase
UA91255C2 (uk) Антивірусні нуклеозиди
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
TW200508220A (en) Hepatitis C inhibitor compounds
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
NO20073706L (no) Hepatitt C virus inhibitorer
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
NO20062185L (no) Hepatitt C virus-inhibitorer
MX2007005176A (es) 5-carboxiamida pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
MX2008001541A (es) Metodos para la preparacion de inhibidores de polimerasa del vhc.
UA84302C2 (ru) Изопентилкарбоксанилиды и способ борьбы с нежелательными микроорганизмами
MX2007001952A (es) Compuestos y composiciones utiles como inhibidores de catepsina-s.
MX2007005177A (es) 5-oxo pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
ATE491706T1 (de) Heterocyclische antivirale verbindungen
CY1114456T1 (el) Αναστολεις ιικης πολυμερασης